Skip to content

The effects of medication induced blood pressure reduction on cerebral hemodynamics in hypertensive frail elderly

The effects of medication induced blood pressure reduction on cerebral hemodynamics in hypertensive frail elderly - BLUEBERRY

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON51539
Enrollment
12
Registered
2022-06-15
Start date
2022-10-12
Completion date
Unknown
Last updated
2024-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

high blood pressure

Interventions

None listed

Sponsors

Radboud Universitair Medisch Centrum
Lead Sponsor

Eligibility

Age
65 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Age >=70 years. - Clinical Frailty Scale >=4 and =150 mmHg without antihypertensive treatment, or; • Uncontrolled systolic hypertension, i.e. office systolic blood pressure >=150 mmHg despite antihypertensive treatment. - Will be starting (untreated) or adding (uncontrolled) antihypertensive treatment in the near future for (further) reducing systolic blood pressure by >=10 mmHg while reaching a treatment target of office systolic blood pressure

Exclusion criteria

Exclusion criteria: - Unable to provide signed and dated informed consent form. - Mentally incompetent subjects (e.g. due to dementia) as assessed by a physician. - Currently enrolled in another interventional study targeting either blood pressure and/or cerebral blood flow. - Cardiovascular event within the past 3 months. - Severe renal disease (eGFR

Design outcomes

Primary

MeasureTime frame
The change in resting CBF from baseline to follow-up (i.e. the average of the in duplo follow-up assessments).

Secondary

MeasureTime frame
- The change in orthostatic tolerance and measures of cerebral autoregulation, i.e. dynamic cerebral autoregulation and baroreflex sensitivity, from baseline to follow-up (i.e. the average of the in duplo follow-up assessments). - The number/percentage of patients that demonstrate a >10% decrease in CBF from baseline to follow-up. - In addition to (reductions in) mean CBF, the number and duration of episodes (during continuous monitoring of CBF) where CBF is reduced by >10% from the mean baseline value.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)